New vaccine strategy aims to shield lymphoma patients from deadly infections
NCT ID NCT04214444
First seen Feb 20, 2026 · Last updated May 23, 2026 · Updated 11 times
Summary
This study tested a two-step pneumococcal vaccine in 26 adults with diffuse large B-cell lymphoma who were receiving rituximab chemotherapy. The goal was to see if giving two different vaccines in sequence could boost protection against serious pneumococcal infections. The approach aimed to improve low vaccination rates and reduce infection risk in these immune-weakened patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, LARGE B-CELL, DIFFUSE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GYAN
Tours, 37044, France
Conditions
Explore the condition pages connected to this study.